The results of the first quarter of the pharmaceutical company's first quarter have been announced. Here's a look at some of the world's drug sales for the first quarter of 2017. 

 

Abbvie's Humria continues to top the list with a big advantage. Gilead Harvoni hepatitis c drug sales fell more, just keep the position in the first 10, but the new anti HCV drugs Epclusa sales reached $892 million in the first quarter, is one of the most popular drug list to go forward. In addition, the drugs with increased sales are also known as the BMS anticoagulants Eliquis, novartis's psoriasis mono-antidrug secukinumab, GSK's anti-hiv drug Tivicay and BMS's ctla-4 inhibitor Yervoy. 

 

Global drug sales Top100 in the first quarter of 2017 

 

 

Note: the red font is the predicted value 

 

Data source: company report